CMPX · Compass Therapeutics, Inc.
Market Cap
$430.41M
Shares
180.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.39
Open$2.40
Day$2.31–2.40
52W close$1.67–6.69
Avg vol 30d3.0M
Short int40.2M · 22.3% float · 9.8d
Short vol51%
Last earningsMay 20, 2026
DataApr 2021–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 26, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−41%
below
Price vs 50-day avg
+9%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
14%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+27%
trailing
6-month return
−57%
trailing
YTD return
−55%
this year
Relative strength
−70%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +64 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.32% of float · ▲ +0.8% MoM · 9.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
216 holders — near 3-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
Free cash flow
$-49.2M
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−75%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−41%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
14%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +64 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.32% of float · ▲ +0.8% MoM · 9.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
216 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $2 · 14%
Range high $7
vs 200-day avg -41%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CMPX
this stock
Compass Therapeutics, Inc.
|
$430.41M | -55.5% | -100.0% | — | 22.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CMPX | -0.4% | +26.8% | -57.1% | +25.1% | -55.5% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -0.9% | +25.6% | -70.4% | +22.5% | -68.0% |